酪酸梭菌二联活菌散联合静注人免疫球蛋白在治疗新生儿溶血性黄疸中的临床应用

Clinical Application of Combined Clostridium Butyricum and Bifidobacterium Powders Combined with Intravenous Human Immunoglobulin in the Treatment of Hemolytic Jaundice of the Newborn

目的:探讨新生儿溶血性黄疸治疗中采用不同方案的价值。方法:纳入90例新生儿溶血性黄疸患者研究(2018年4月~2021年4月),按双盲法分为对照组(采用人免疫球蛋白静注治疗)和观察组(采用酪酸梭菌二联活菌散联合人免疫球蛋白治疗)各45例,统计两组临床疗效、临床指标、生长发育情况、不良反应率。结果:临床疗效方面,观察组(95.56%)高于对照组(82.22%),组间对比P<0.05。临床指标方面,观察组治疗后TBIL、Hb低于对照组,神经行为评分、神经发育情况评分高于对照组,组间对比差异显著(t 1=11.187,P 1<0.001;t 2=3.835,P 2<0.001;t 3=13.816,P 3<0.001;t 4=4.237,P 4=0.003)。生长发育情况方面,观察组治疗后身长、体质量、头围高于对照组,组间对比差异显著(t 1=11.597,P 1<0.001;t 2=21.423,P 2<0.001;t 3=18.558,P 3<0.001)。不良反应率方面,观察组(2.22%)与对照组(0.00%)相比无差异,组间对比P>0.05。结论:酪酸梭菌二联活菌散联合静注人免疫球蛋白在新生儿溶血性黄疸治疗中效果确切,可促进其生长发育,亦可改善胆红素指标,提高治疗安全性及有效性。

Objective:To investigate the value of different protocols in the management of hemolytic jaundice in newborns.Methods:90 neonatal hemolytic jaundice patients were included in the study(April 2018 to April 2021)and divided into control group(n=45,treated with intravenous human immunoglobulin)and observation group(n=45,treated with Combined Clostridium Butyricum and Bifidobacterium Powders combined with intravenous administration of human immunoglobulin)according to the double-blind method.The clinical efficacy,clinical parameters,growth and development status,and the incidence of adverse reactions of the two groups were calculated.Results:Clinical efficacy:It was higher in the observation group(95.56%)than in the control group(82.22%)(P<0.05).Clinical parameters:TBIL and Hb were lower and neurobehavioral and neurodevelopmental scores were higher in the observation group than in the control group,with significant difference between thie two groups(t 1=11.187,P 1<0.001;t 2=3.835,P 2<0.001;t 3=13.816,P 3<0.001;t 4=4.237,P 4=0.003).Growth and development:The height,body mass,and head circumference were higher in the observation group than in the control group,with significant difference between the two groups(t 1=11.597,P 1<0.001;t 2=21.423,P 2<0.001;t 3=18.558,P 3<0.001).Incidence of adverse reactions:There was no difference between the observation group(2.22%)and the control group(0.00%)(P>0.05).Conclusion:The application of Combined Clostridium Butyricum and Bifidobacterium Powders combined with intravenous human immunoglobulin is effective in the treatment of hemolytic jaundice of neonates,which can promote the growth and development,also improve the bilirubin index,and improve the safety and efficacy of treatment.